Megan McNamara

Positions:

Assistant Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2010

University of North Carolina at Chapel Hill School of Medicine

Internal Medicine Residency, Medicine

Duke University School of Medicine

Hematology/Oncology Fellowship, Medicine

Duke University School of Medicine

Grants:

PCRP Clinical Consortium: Duke University Clinical Research Site

Administered By
Medicine, Medical Oncology
Awarded By
Department of Defense
Role
Co Investigator
Start Date
End Date

An IND-enabling Trial to Determine the Number and Volume of Injections Necessary for Adequate Distribution Throughout Cancer Metastases and to Validate Poliovirus Receptor (CD155) Expression in PC

Administered By
Medicine, Medical Oncology
Awarded By
V Foundation for Cancer Research
Role
Principal Investigator
Start Date
End Date

Bayer-Exini Radium-223 Retrospective Study

Administered By
Duke Cancer Institute
Role
PI-Fellow
Start Date
End Date

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint i

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

PCF Young Investigator Award

Administered By
Medicine, Medical Oncology
Role
Principal Investigator
Start Date
End Date

Publications:

The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.

BACKGROUND: Until 2015, androgen deprivation therapy (ADT) alone was the standard-of-care for metastatic hormone-sensitive prostate cancer (mHSPC). In 2015, the CHAARTED and STAMPEDE-Docetaxel studies demonstrated marked survival benefit with the addition of docetaxel to ADT in the mHSPC setting, leading to a change in the standard-of-care for mHSPC. The recent LATITUDE and STAMPEDE-Abiraterone trials showed similar substantial improvement in survival with the addition of abiraterone plus prednisone to ADT in this space. METHODS: We conducted a review of the randomized phase III studies that have investigated either the addition of docetaxel or abiraterone to ADT in patients with mHSPC. RESULTS: We describe the study designs, key eligibility criteria, and key results for the CHAARTED, STAMPEDE-Docetaxel, GETUG-AFU 15, LATITUDE, and STAMPEDE-Abiraterone clinical trials. We compare the data for abiraterone/prednisone plus ADT in mHSPC with the evidence for docetaxel plus ADT in these patients. Finally, we discuss several factors that should be considered when choosing between docetaxel/ADT or abiraterone/prednisone/ADT in mHSPC. CONCLUSIONS: The management of mHSPC is evolving. Abiraterone plus prednisone in addition to ADT has emerged as an alternative standard-of-care to docetaxel plus ADT, and ongoing trials should clarify whether combination vs. sequential approaches with AR-targeting agents and taxane chemotherapy are preferred for initial management in the hormone-sensitive setting.
Authors
McNamara, M; Sweeney, C; Antonarakis, ES; Armstrong, AJ
MLA Citation
McNamara, Megan, et al. “The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation..” Prostate Cancer Prostatic Dis, vol. 21, no. 3, Sept. 2018, pp. 306–18. Pubmed, doi:10.1038/s41391-017-0014-9.
URI
https://scholars.duke.edu/individual/pub1293589
PMID
29263421
Source
pubmed
Published In
Prostate Cancer Prostatic Dis
Volume
21
Published Date
Start Page
306
End Page
318
DOI
10.1038/s41391-017-0014-9